Abstract

Simple SummaryThe OSov web server incorporates gene expression profiles with clinical risk factors to estimate the ovarian cancers patients’ survival, and provides a tool for multiple analysis, such as forest-plot, uni/multi-variate survival analysis, Kaplan-Meier plot and nomogram construction.Ovarian cancer is one of the most aggressive and highly lethal gynecological cancers. The purpose of our study is to build a free prognostic web server to help researchers discover potential prognostic biomarkers by integrating gene expression profiling data and clinical follow-up information of ovarian cancer. We construct a prognostic web server OSov (Online consensus Survival analysis for Ovarian cancer) based on RNA expression profiles. OSov is a user-friendly web server which could present a Kaplan–Meier plot, forest plot, nomogram and survival summary table of queried genes in each individual cohort to evaluate the prognostic potency of each queried gene. To assess the performance of OSov web server, 163 previously published prognostic biomarkers of ovarian cancer were tested and 72% of them had their prognostic values confirmed in OSov. It is a free and valuable prognostic web server to screen and assess survival-associated biomarkers for ovarian cancer.

Highlights

  • As one of the most aggressive gynecological cancers with a high fatality rate, the effective screening regimen for ovarian cancer is yet to be established, and the long-term prognosis has not dramatically changed in the past 20 years [1,2]

  • Those clinical factors are useful information to stratify the risk of ovarian cancer patients and to estimate clinical outcomes based on the traditional therapy

  • The summary of clinicopathological features of total ovarian cancer cases were presented in Tables 1 and 2, showing that 75% ovarian cancer patients are diagnosed with serous cancer, which exhibits the worst overall prognostic survival than that of other histological types (Table 1 and Figure 1A)

Read more

Summary

Introduction

As one of the most aggressive gynecological cancers with a high fatality rate, the effective screening regimen for ovarian cancer is yet to be established, and the long-term prognosis has not dramatically changed in the past 20 years [1,2]. Ovarian cancer has four histological subtypes, including serous, endometrioid, clear cell and mucinous carcinoma. High-grade serous carcinoma comprises 70% of ovarian cancers with the worst survival rate, present in older women with advanced disease (stage III or IV) and TP53 mutations. Low-grade serous carcinoma is present in young women with a better prognosis, responding poorly to chemotherapy. Endometrioid adenocarcinoma and clear cell carcinoma representatively display histological stage I/II and are frequently related to pelvic endometriosis. Mucinous carcinoma is a fairly uncommon tumor with highly variable outcome [3]. There is an urgent need to develop prognostic biomarkers for ovarian patients to predict clinical outcome, identify high-risk patients and guide clinical management

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call